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Abstract 
 
Stress has been identified as a common trigger for psychosis. Dopamine pathways are 
suggested to be affected by chronic and severe stress and to play an important role in 
psychosis. This pilot study investigates the potential relationship of stress and psychosis in 
subclinical psychotic experiences. It was hypothesised that single nucleotide polymorphisms 
(SNPs) previously found to be associated with psychiatric disorders would be associated with 
both stress and subclinical psychotic experiences. University students (N = 182) were 
genotyped for 17 SNPs across 11 genes. Higher stress reporting was associated with rs4680 
COMT, rs13211507 HLA Region, and rs13107325 SLC39A8. Reports of higher subclinical 
psychotic experiences were associated with DRD2 SNPs rs17601612 and rs658986 and an 
AKT1 SNP rs2494732. Replication studies are recommended to further pursue this line of 
research for identification of markers of psychosis for early diagnosis and intervention. 
 
Keywords: subclinical psychotic experiences, stress, COMT, DRD2, AKT1, SLC39A8, HLA 
region. 
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Introduction 
Psychosis, including severe psychotic disorders such as schizophrenia, carries a high 
health and societal burden (Kelleher & Cannon, 2010; van Os & Kapur, 2009; Suvisaari et 
al., 2009). During transition to adulthood psychotic symptoms are most likely to emerge 
(Insel, 2010). Research into this age group has been limited (McGorry, 2011) with most 
research focussing on childhood and young adolescence (e.g., Taylor et al., 2011, Wigman 
et al., 2011; for a review, see McGorry, 2011).  
Stress has been identified as a pivotal marker for onset and more severe presentation 
of psychosis (Corcoran et al., 2003). Psychological stress is a state in which an individual’s 
coping resources are exceeded resulting in potentially compromised well-being (Lazarus 
and Folkman, 1984). Heightened vulnerability to stress is associated with the stages of 
puberty and transition into adulthood because of neurobiological changes and life events 
(McGorry, 2011; Schulenberg et al., 2004; Spear, 2009).  
Stress has also been identified as a marker for the occurrence of subclinical 
psychosis in a large-scale female twin study (Lataster et al., 2009). Subclinical psychotic 
experiences are common in the general population and phenotypically and dimensionally 
similar to severe psychotic experiences (e.g. Stefanis et al., 2002; Nuevo et al., 2012). They 
are suggested to precipitate a severe mental disorder coupled with increased environmental 
stressors (Cougnard et al., 2007).  
Associations between stress and schizophrenia have been investigated using the 
vulnerability of stress model (Tsoi et al., 2008; Yuii et al., 2007): Vulnerability is either 
inborn (genetic predisposition) or acquired (environmental influences) and could potentially 
trigger psychosis (Zubin & Spring, 1977). Neurobiological findings suggest that early 
neurobiological or traumatic stressors impact on the hormonal pathways through the stress 
cascade of the HPA (hypothalamic-pituitary-adrenal) axis, influencing the dopamine 
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pathway and leaving individuals more prone to experiencing stress at a heightened level 
(Lee & Schepp, 2009; Walker & DiForio, 1997). 
A dysfunction in the dopamine pathway has been associated with schizophrenia as 
dopamine is hypothesized to regulate emotional stability (for a review, see Salgado-Pineda, 
et al., 2005). Dopaminergic activity is influenced by many SNPs, e.g. within the protein 
kinase AKT1gene, Catechol-O-methyl transferase gene (COMT), and dopamine D2 receptor 
gene (DRD2). COMT’s involvement in dopamine clearance in the pre-frontal cortex, an area 
associated with cognitive impairment in schizophrenia, suggests a role in the development 
of schizophrenia and similar disorders (for a review, see Williams et al., 2007). COMT 
SNPs, especially rs4680, have been repeatedly identified as associated with schizophrenia 
(e.g., Egan et al., 2001; Voisey et al., 2010c). DRD2, in particular the rs6277 
polymorphism, has been associated with higher risk of schizophrenia (Lawford et al., 2005, 
Betcheva et al., 2009; Dubertret et al., 2010; Fan et al., 2010, for a meta-analysis see 
Monakhov et al., 2008), with an increase of receptor availability found in a sample of 
patients with schizophrenia (Seeman & Kapur, 2000). AKT1 has shown to influence the 
dopamine pathway (Beaulieu et al., 2009), and gene variants of AKT1 have also been 
associated with schizophrenia and other mood disorders (Emamian et al., 2004; Karege et 
al., 2012).  
It has been proposed that dysfunction of the glutamatergic system negatively 
influences the dopamine pathway. Animal models and preclinical studies (Patil et al., 2007) 
as well as human gene studies (Voisey et al., 2010a) support this notion. For example, 
Dystrobrevin binding protein 1 gene (DTNBP1, dysbindin), central in the regulation of the 
glutamatergic system was found to be significantly associated with schizophrenia both at the 
allele and genotype level (SNP rs9370822; Voisey et al., 2010a). The short version of the 
CAPON gene (carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase) within the 
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glutamatergic system, is associated with both schizophrenia and bipolar disorder (e.g., Xu et 
al., 2005), post-traumatic stress disorder (PTSD) and severe depression in PTSD (Lawford 
et al., 2013). The HLA (Human leucocyte antigen) region is usually associated with immune 
system function and a genome-wide study found associations of this region in the 
development of schizophrenia (Schizophrenia Consortium, 2009). A review of published 
associations of the HLA region with psychiatric disorders suggest that this area is of interest 
in further elucidating aetiology of psychiatric disorder (Corvin & Morris, 2014).  In 
particular this review outlined the need for the identification of causative HLA SNPs and 
their functions to explain the pathogenesis of schizophrenia.   
Given their associations with psychosis and their roles in the broader dopamine 
system, these genes are strong candidates to explore the association between stress, 
subclinical psychotic experiences and genetic predisposition as had previously been 
proposed (van Winkel et al., 2008). One study observed shared genetic risk for stress and 
schizophrenia on the COMT gene (Collip et al., 2011). Voisey et al. (2010b) found shared 
genetics risk for schizophrenia and PTSD on the DTNBP1 gene. Another study researched 
shared genetics risk for bipolar disorders and cardio-vascular disease that are commonly 
associated with stress and found moderate effect sizes (Ising & Holsboer, 2006). Recently, 
the Cross-Disorder Group of the Psychiatric Genomics Consortium (2013) found that 
specific SNPs are associated with a range of psychiatric disorders with both childhood and 
adulthood onset. 
This exploratory study aimed to investigate if genes involved in the wider dopamine 
system are associated with stress and psychotic experiences in a healthy sample. It was 
predicted that dopamine system-related SNPs associated with psychotic disorders would be 
associated with higher reporting of stress and subclinical psychotic experiences.  
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Materials and Methods 
Participants 
Participants (N = 182) were recruited from the Queensland University of Technology 
through flyers, lectures, and individual approach on campus. Selection criteria included 
having sufficient English skills to complete assessments, being aged between 17 and 25 
years of age, no reported history of brain injury and Caucasian ethnicity. The mean age of 
this sample was 20.48 years (SD = 2.48). The majority of participants were female (70.3%).  
Participants received information about the nature of the study and data collection. 
Written consent was obtained before data collection began. Ethics approval for the project 
was obtained from the Human Research Ethics Committee of the Queensland University of 
Technology.  
The participant questionnaire contained demographic information, measures for 
stress reporting, and subclinical psychotic experiences. 
The Chronic Stress Scale (CSS) measures ongoing psychological stress over the past 
six months in seven categories: marital, parental, filial, financial, occupational, ecological 
and physical (Norris & Uhl, 1993). The total scale has good internal reliability with an 
overall Cronbach’s alpha of .83 (Norris & Uhl, 1993). For the current study, five subscales 
were chosen, modified and renamed as per White (2011) to capture the target group of this 
study: marital stress changed to relationships, filial stress to family, financial stress to 
finances, occupational stress changed to ‘work and study stress’, and, without modification, 
physical stress. The 18 items are rated on a five point Likert scale from 0 = never to 4 = very 
often.  
The Community Assessment of Psychic Experiences (CAPE) scale consists of two 
parts measuring subclinical psychotic experiences and their impact (qualifying subscale) in 
the general population (Stefanis et al., 2002). It has sound test-retest reliability and 
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discriminant validity (Konings et al., 2006). The scale has 42 items rated on a four point 
Likert scale:0 = never to 3 = nearly always. The qualifying subscale was not used for 
analysis.  
SNP Selection and Genotyping 
DNA was obtained by collection of a saliva sample using Oragene kits (DNA 
Genotek Inc., Kanata). A total of 18 SNPs were selected from 11 genes previously 
associated with schizophrenia. A list of the SNPs and the associated gene is displayed in 
Table I.  
Samples were genotyped using a homogeneous MassEXTEND (hME) Sequenom 
assay performed by the Australian Genome Research Facility. The hME assay is based on 
the annealing of an oligonucleotide primer (hME primer) adjacent to the SNP of interest. 
The addition of a DNA polymerase along with a mixture of terminator nucleotides allows 
extension of the hME primer through the polymorphic site and generates allele-specific 
extension products, each having a unique molecular mass. The resultant masses of the 
extension products are then analysed by matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS) and a genotype is assigned in real time. Six 
SNPs had fails: rs4680 (1.65%), rs165774 (1%), rs6277 (0.55%), rs6589386 (6%), 
rs3803300 (2.2%), rs1315259 (0.55%). All other SNPs had a pass rate of 100%. 
Statistical Analysis 
A priori power calculations for one-way analyses of variance (ANOVAs) of three 
groups showed a sample size of 159 was necessary for acceptable power of .80 and a small 
effect size of .2 per SNP. 
All analyses were performed using SPSS Statistic Package 18 for MacIntosh 
Computers and SPSS 19 for PCs. Calculations for Hardy-Weinberg-Equilibrium were 
performed using the Utility Programs for Analysis of Genetic Linkage (Ott, 1988). Odds 
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ratios were calculated using COMPARE2 program from the WinPepi suite of epidemiology 
programs (Abramson, 2004). All data were screened for entry errors, missing values and 
breaches of assumptions. Little’s Missing Completely At Random test was non-significant 
(χ2= 1465.83, p = .47) indicating that data was missing at random. Missing data were 
excluded list-wise. An alpha level of .05 was applied to determine significance unless 
otherwise specified.  
Descriptive analysis for the CSS score distribution revealed a mean of 19.02 (SD = 
8.62). Normality for the CSS distribution was accepted upon visual inspection. Internal 
reliability for the CSS scale was acceptable (Cronbach’s α = .74).  
The CAPE distribution was bi-modal and a split at a median of 47 was performed to 
create two groups for further analysis. While this approach can reduce statistical power, 
other modes of analysis yielded unsatisfactory model fits. Reliability of the CAPE 
frequency scale was very high (Cronbach’s α = .98), as expected with the large number of 
items (Cortina, 1993). Moderate to high correlations between the subscales of the CAPE 
have previously been reported. Subclinical psychotic experiences in the general population 
are probably more attenuated than in clinical samples (Stefanis et al., 2002). 
Results 
Chronic stress scale (CSS)  
ANOVAs were performed individually for the effects of 18 SNPs on CSS scores. 
Three SNPs, rs4680 (COMT), rs13211507 (HLA Region), and rs13107325 (SLC39A8), 
were associated with higher stress scores. Results of the ANOVAs for all 18 SNPs are 
shown in Table II.  
Post-hoc tests with Bonferroni and Tukey adjustment were performed for the 
significant SNPs. For the rs13107325 SNP, participants with genotype CC (n = 144) had a 
significantly higher mean score on the CSS (M = 19.84, SD = 8.64) than those with 
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genotype CT (n = 30; M = 15.23, SD = 7.66; Tukey p = .02, 95% CI [-.57, 8.64]; Bonferroni 
p = .02, 95% CI [.48, 8.73]). There was no significant difference in means between 
genotypes CC and TT or CT and TT (n = 2). Findings for genotype TT need to be 
interpreted with caution as there were only two cases. Figure 1 shows the CSS mean scores 
per genotype. 
For rs13211507, participants with genotype TT (n = 153; M = 19.56, SD = 8.73) had 
significantly higher CSS mean scores than genotype CT (n = 25; M =15.68, SD = 7.15). 
Figure 1 shows the CSS mean scores per genotype.  No CC genotypes were reported.   
For rs4680, participants with genotype AG (n = 93) had significantly higher means 
(M = 20.76, SD = 8.98) than those with genotype AA (n = 46, M = 16.93, SD = 7.24; Tukey 
p = .03, 95% CI [.22, 7.44]; Bonferroni p = .04, 95% CI [.14, 7.51]). There was no 
significant difference between genotypes AA and GG (n = 36) or AG and GG (Figure 1).  
Genotype frequencies indicated that all three significant SNPs were in Hardy-
Weinberg-Equilibrium. None of the three SNPs survived correction for multiple testing with 
the Benjamini-Hochberg model (Benjamini & Hochberg, 1995). 
CAPE scores  
Chi-Square analysis was performed for each of the 18 SNPs by CAPE score group. 
Three SNPs, rs17601612 DRD2, rs2494732 AKT1, and rs6589386 DRD2 were significantly 
associated (p = 0.009, p = 0.02, p = 0.03, respectively) with higher levels of psychotic 
experiences. Chi-Square results for all 18 SNPs are shown in Table III.  
Odds ratios were calculated yielding high ratios. Tables IV, V, and VI show 
genotype frequencies of rs17601612, rs2494732, and rs6589386 respectively, for 
participants reporting higher levels compared with those reporting lower levels of psychotic 
experiences. For rs17601612, participants with genotype CC were five times more likely to 
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report psychotic experiences than those with genotypes GG or CG. Odds ratios between CG 
and GG were not significantly different (Table IV). 
For rs2494732, participants with genotype CC were four times more likely to report 
psychotic experiences than those with genotypes CT and TT. Odds ratios for CT and TT 
were not significantly different (Table V). 
For rs6589386, participants with genotype CC were three times more likely to report 
psychotic experiences than those with genotypes CT and TT (approaching significance, p = 
.05). Participants with genotype CT were three times more likely to report psychotic 
experiences than participants with genotype TT (Table VI).  
All three SNPs were in Hardy-Weinberg-Equilibrium. After multiple testing using 
Benjamini-Hochberg methodology (Benjamini & Hochberg, 1995), none of the SNPs 
maintained significance.  
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Discussion 
The aim of this pilot study was to investigate the relationship between stress and 
subclinical psychotic experiences and genetic predisposition in a healthy sample of young 
adults. Stress has been identified as a strong marker of onset and maintenance of clinical 
psychosis (Corcoran et al., 2003). Physiologically, the dopamine system has been implied to 
play a role in psychosis (Salgado-Pineda et al., 2005) and to be affected by stress (Lee & 
Schepp, 2009; Walker & DiForio, 1997). This led to the assumption of shared genetics 
between psychosis and stress (van Winkel et al., 2008).  
Subclinical psychotic experiences have been found with high prevalence in the 
general population (e.g., Nuevo et al., 2012) with strong similarities to clinical psychosis 
(Stefanis et al., 2002). They are suggested to be a potential early marker for the 
development of clinical psychosis (Cougnard et al., 2007; Mossaheb et al., 2012). This 
study found partial support for these assumptions in that SNPs previously associated with 
schizophrenia were found to play a role both in chronic stress and subclinical psychotic 
experiences. 
Our hypothesis focused on findings from genetic research that a variety of genes 
and corresponding SNPs influence the broader dopamine system, potentially increasing risk 
for psychotic disorders. Shared genetics of the dopamine system between patients and 
healthy controls might also influence stress response (van Winkel et al., 2008). Our results 
suggest that both assumptions are worthy of further investigation. Three SNPs, rs13107325, 
rs13211507, and rs4680 were found to be significantly associated with CSS scores. SNPs 
rs17601612, rs2494732, and rs6589386 yielded significant associations with high ratings on 
the CAPE scale. However, none of the SNPs withstood corrections for multiple testing, 
likely due to the large number of SNPs analysed in this study and moderate sample size. An 
association of genes potentially involved in psychotic disorders and stress had been 
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proposed previously (van Winkel et al., 2008). The non-synonymous SNP rs4680 of the 
COMT gene has been associated with stress (Collip et al., 2011) indicating that stress 
sensitivity may be a useful marker of liability to psychosis.  
Involvement of rs13211507 located in the HLA Region with chronic stress suggests 
an association with immune system function that requires further investigation. Previous 
research has identified associations with intense stress resulting from a traumatic event and 
the immune system (see Andrews & Neises, 2012, Jones & Thomsen, 2013 for reviews). 
This SNP and other SNPs located in chromosome 6 are associated with schizophrenia (e.g. 
Stefansson et al., 2009; for a review see Ozomaro et al., 2013).  
We also identified association of rs13107325 located in the SLC39A8 gene with 
chronic stress. The SLC39A8 gene is responsible for transport of important metals that play 
a role in brain development and function (He et al., 2006). Deletion of SLC39A8 has been 
associated with mental retardation and other SLC39 regions might be involved in 
psychiatric disorders such as bipolar disorder (Ollila et al., 2009) and major depressive 
disorder (Muglia et al., 2010). More research is needed to understand the association of the 
SLC39A8 SNP rs13107325 (Carrera et al., 2012). 
Genetic associations with CAPE scores showed significance for two DRD2 SNPs 
and one AKT1 SNP. Both genes influence the dopamine system and might be important for 
emotion-regulation (e.g., Salgado-Pineda et al., 2005). Both genes have been extensively 
studied for their role in psychotic disorders (e.g., Egan et al., 2001 for AKT1; Lawford et al., 
2005 for DRD2). In a cohort of participants with a life-time diagnosis of psychosis AKT1 
SNP rs2494732 showed strong association with psychosis rather than bipolar disorder 
(Karege et al., 2012). The association of these genes with subclinical psychotic experiences 
suggests that genetic predisposition heightens risk for people with specific genotypes 
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(Stefanis et al., 2001). The high odds ratios reported suggest genetic predisposition to be an 
important factor in developing subclinical psychotic experiences.  
These findings should be interpreted with caution. This pilot study was based on a 
convenience sample with a strong bias towards female participation with modest participant 
numbers. Additional data collection will be needed to obtain greater statistical power and 
robustness. Because of the large number of SNPs tested and the modest sample size, none of 
these findings withstood multiple testing. The study did not investigate potential mediator 
and moderator variables, such as gender and substance use, due to the modest sample size 
and limited power. Investigating potential interactions could be important to better 
understand the data.  
In general, findings of this pilot study form an encouraging basis for further 
research into the relationship of stress, genetic predisposition and subclinical psychotic 
experiences. Genetic predisposition led to increased experience of subclinical psychotic 
experiences and higher stress ratings. If shared genetic risk between psychotic disorders, 
subclinical psychotic experiences and stress is confirmed, high-risk individuals with a 
family history of psychotic disorders and patients suffering from stress-influenced disorders 
may particularly benefit through early diagnosis (Gask et al., 2008; Mossaheb et al., 2012), 
prevention and early stress management (Betensky et al., 2007).  
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Figure 1. Associations of genotype and chronic stress (CSS scores) for SNPs rs13107325 
SLC39A8, rs13211507 HLA Region, and rs4680, COMT 
Figure 1 
 
 
rs13107325 rs13211507 rs4680
0
5
10
15
20
25
TT CT CC TT CT CC GG AG AA
CS
S 
M
ea
n 
Sc
or
es
Genotypes
rs13107325
rs13211507
rs4680
 
  
25 Bruenig 
 
Table I 
Candidate SNPs selected for analysis 
 
SNP1 Gene Biological function 
Rs4680 COMT Dopaminergic role 
Rs165774 COMT Dopaminergic role 
Rs17601612 DRD2 Dopaminergic role 
Rs6277 DRD2 Dopaminergic role 
Rs6589386 DRD2 Dopaminergic role 
Rs1800497 ANKK1 Dopaminergic role 
Rs2494732 AKT1 Dopaminergic role 
Rs3803300 AKT1 Dopaminergic role 
Rs4975646 DAT Dopaminergic role 
Rs1415259 CAPON Glutamatergic role 
Rs386231 CAPON Glutamatergic role 
Rs6683968 CAPON Glutamatergic role 
Rs9370822 DTNBP1 Glutamatergic role 
Rs4263535 GABRA1 GABAergic role 
Rs7341475 RELN GABAergic role 
Rs2273816 KPNA3 Nuclear protein import 
Rs13107325 SLC39A8 Zinc transporter 
Rs13211507 HLA region Immune System 
1SNP = single nucleotide polymorphism  
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Table II  
Univariate ANOVA Results for Chronic Stress (CSS scores) by 18 SNPs1 
SNP2 Gene 
Name 
Df3 F p η2 
Dopaminergic role 
rs4680 COMT 2,172 3.79 .02 .04 
rs165774 COMT 2,173 1.25 .29 .01 
rs17601612 DRD2 2,175 1.86 .16 .02 
rs6277 DRD2 2,174 1.29 .28 .01 
rs6589386 DRD2 2,165 .12 .89 .00 
rs1800497 ANKK1 2,175 1.90 .15 .02 
rs2494732 AKT1 2,175 .47 .63 .00 
rs3803300 AKT1 2,171 .80 .45 .01 
rs4975646 DAT 2,175 .41 .66 .01 
 
Glutamatergic role 
rs1415259 CAPON 2,174 .84 .43 .01 
rs386231 CAPON 2,175 .97 .38 .01 
rs6683968 CAPON 2,175 1.03 .36 .01 
rs9370822 DTNBP1 2,175 .51 .60 .01 
 
GABAergic role 
rs4263535 GABRA1 2,175 .12 .88 .00 
rs7341475 RELN 2,175 .64 .53 .01 
 
Nuclear Protein Import 
rs2273816 KPNA3 2,175 .19 .83 .00 
 
Zinc Transporter 
rs13107325 SLC39A8 2,173 3.70 .04 .04 
 
HLA Region 
rs13211507  1,176 4.45 .04 .025 
1N = 182,  
2SNP = Single nucleotide polymorphism,  
3df = Degrees of freedom 
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Table III 
Chi-Square results for Subclinical Psychotic Experiences (CAPE scores) 
SNP1 Gene Name Df2 χ2 P 
Dopaminergic role     
rs4680 COMT 2 3.94 .14 
rs165774 COMT 2 1.95 .38 
rs17601612 DRD2 2 9.43 .009 
rs6277 DRD2 2 2.70 .26 
rs6589386 DRD2 2 7.27 .03 
rs1800497 ANKK1 2 3.56 .17 
rs2494732 AKT1 2 7.64 .02 
rs3803300 AKT1 1 .00 1.0 
rs4975646 DAT 2 .16 .92 
     
Glutamatergic role     
rs1415259 CAPON 2 3.85 .15 
rs386231 CAPON 2 1,66 .47 
rs6683968 CAPON 2 1.82 .40 
rs9370822 DTNBP1 2 .10 .95 
     
GABAergic role     
rs4263535 GABRA1 2 2.61 .27 
rs7341475 RELN 2 2.00 .37 
     
Nuclear Protein Import     
rs2273816  2 5.58 .06 
     
Zinc Transporter     
rs13107325 SLC39A8 2 1.47 .48 
     
HLA Region     
rs13211507  1 2.69 .10 
1SNP = Single nucleotide polymorphism, 2df = Degrees of freedom 
 
Table IV  
Association of Genotype Frequencies of rs17601612 for Participants with High and Low 
Levels of Subclinical Psychotic Experiences (CAPE scores) 
 
rs17601612 Genotype counts (%) 
 GG CG CC 
Low levels 35 (62.5) 22 (25.4) 4 (8.3) 
High levels 21 (37.5) 30 (57.7) 13 (76.5) 
Odds ratio 1 2.27 5.42 
(p value)  (.07) (.008) 
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Table V  
Association of Genotype Frequencies of rs2494732 for Participants with High and Low 
Levels of Subclinical Psychotic Experiences (CAPE scores) 
 
rs2494732 Genotype counts (%) 
 TT CT CC 
Low levels 26 (61.9) 29 (48.3) 6 (26.1) 
High levels 16 (38.1) 31 (51.7) 17 (73.9) 
Odds ratio 1 1.73 4.60 
(p value)  (.35) (.01) 
 
 
Table VI  
Association of Genotype Frequencies of rs6589386 for Participants with High and Low 
Levels of Subclinical Psychotic Experiences (CAPE scores) 
 
rs6589386 Genotype counts (%) 
 TT CT CC 
Low levels 20 (74.1) 29 (44.6) 12 (44.4) 
High levels 7 (25.9) 36 (55.4) 15 (55.6) 
Odds ratio 1 3.55 3.57 
(p value)  (.02) (.05) 
 
 
